Product Description
UM171 patients benefit from rapid T cell reconstitution, which likely contributes to the absence of moderate/severe cGVHD, infection-related mortality, and late TRM observed in this cohort. Recently, results of a phase I/II trial revealed that single UM171-expanded CB transplant allowed the use of smaller CB units without compromising engraftment (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33022376/)
Mechanisms of Action: Cell Therapy, CD34
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ExCellThera inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Netherlands, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Allogeneic Stem Cell Transplant|Graft vs Host Disease|Hematopoietic Stem Cell Transplant|Myelodysplastic Syndrome|Preleukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04990323 |
ECT-001-CB.007 | P2 |
Recruiting |
Hematopoietic Stem Cell Transplant|Graft vs Host Disease |
2026-06-01 |
2% |
2024-02-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2024-517583-36-01 |
ECT-001-CB.004 | P2 |
Not yet recruiting |
Allogeneic Stem Cell Transplant|Myelodysplastic Syndrome |
2026-02-15 |
2025-05-02 |
Treatments |
|
NCT04103879 |
ECT-001-CB.004 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Preleukemia |
2026-02-01 |
2% |
2024-02-21 |
Primary Completion Date|Primary Endpoints |